Q1 2026

Filed May 6, 2026 · 10-Q · 36 days after period end · 0001802768-26-000009

Q1 2026 · 10-Q

Revenue

$630.58M

+11.0% vs Q1 2025

Net Income

$294.69M

+23.1% vs Q1 2025

EPS Diluted

$0.67

+21.8% vs Q1 2025

Operating Income$563,038,000+5.4%

Operating Cash Flow

Same quarter

Metric	Q1 2026	Q1 2025	Q1 2024	Q1 2023
Revenue	$630.58M	$568.25M	$567.98M	$683.97M
Net Income	$294.69M	$239.35M	$4.78M	$340.76M
EPS Diluted	$0.67	$0.55	$0.01	$0.76

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Royalty Pharma plc · CIK 1802768 · Engraved from SEC EDGAR